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Abstract
Dysphagia after primary chemoradiotherapy or radiation alone in pharyngeal cancers can have a devastating impact on a patient’s physical, social and emotional
state. Establishing and validating efﬁcient dysphagia-optimised radiotherapy techniques is, therefore, of paramount importance in an era where health-related
quality of life measures are increasingly inﬂuential determinants of curative management strategies, particularly as the incidence of good prognosis, human
papillomavirus-driven pharyngeal cancer in younger patients continues to rise. The preferential sparing achievable with intensity-modulated radiotherapy
(IMRT) of key swallowing structures implicated in post-radiation dysfunction, such as the pharyngeal constrictor muscles (PCM), has generated signiﬁcant
research into toxicity-mitigating strategies. The lack of randomised evidence, however, means that there remains uncertainty about the true clinical beneﬁts of
the dosimetric gains offered by technological advances in radiotherapy. As a result, we feel that IMRT techniques that spare PCM cannot be incorporated into
routine practice. In this review, we discuss the swallowing structures responsible for functional impairment, analyse the studies that have explored the dos-
eeresponse relationship between these critical structures and late dysphagia, and consider the merits of reported dysphagia-optimised IMRT (Do-IMRT) ap-
proaches, thus far. Finally, we discuss the dysphagia/aspiration-related structures (DARS) study (ISRCTN 25458988), which is the ﬁrst phase III randomised
controlled trial designed to investigate the impact of swallow-sparing strategies on improving long-term function. To maximise patient beneﬁts, improvements
in radiation delivery will need to integrate with novel treatment paradigms and comprehensive rehabilitation strategies to eventually provide a patient-centric,
personalised treatment plan.
Crown Copyright  2017 Published by Elsevier Ltd on behalf of The Royal College of Radiologists. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).
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cancers, dysphagia-optimised IMRT, head and neck cancer,
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through searching reference lists for included studies.Introduction
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survivors living with devastating long-term functional im-
pairments [4], paradoxically as a result of ‘organ-preserving’
primary chemoradiotherapy (CRT) or radiotherapy alone.
Radiotherapy-induced dysphagia represents a substantial
burden in this context, with nearly 50% of patients high-
lighting it as a distressing symptom a year after treatment
completion [5]. Persistent swallowing dysfunction leads to
increased aspiration risks, which is typically under-reported
in most head and neck cancer (HNC) trials, where assess-
ments are undertaken only at the onset of clinical symp-
toms, thereby failing to identify patients who aspirate
silently, and detected only after incidental objective evalu-
ation. Other consequences of swallowing dysfunction
include prolonged feeding tube dependence, psychological
disturbances and worsened health-related quality of life
(HR-QoL) [6e13]. In comparisonwith radiotherapy, primaryyal College of Radiologists. This is an open access article under the CC BY-NC-
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yngeal cancers, where severe tumour-related symptoms
compromise organ function; and in T1-2 N0 oropharyngeal
cancers (OPC), where minimally invasive transoral surgery
in conjunction with neck dissection might be an alternate
function-preserving, less morbid therapeutic option [14].
However, a signiﬁcant proportion of patients treated with
transoral surgery require adjuvant radiotherapy-based
treatment, thereby undermining the beneﬁts of primary
surgery [15]. There is, therefore, a real risk that current
treatment approaches will lead to a generation of cured
patients who are ‘pharyngeal cripples’ [16], and we feel that
there is an urgent unmet need to devise efﬁcient swallow-
sparing radiotherapy strategies in pharyngeal cancer.
The introduction of ﬁxed-ﬁeld intensity-modulated
radiotherapy (IMRT), with its ability to sculpt complex dose
distributions, has revolutionised radiation delivery for
pharyngeal cancer in the last decade. IMRT has been shown
to improve HR-QoL by reducing long-term xerostomia,
without compromising locoregional control [17]. Increas-
ingly, there is a focus to establish dysphagia-optimised
IMRT (Do-IMRT) strategies [18], which could translate into
improved long-term symptom burden outcomes for
pharyngeal cancer patients by reducing dose to critical
swallowing structures. Reﬁnements to existing technology,
in the form of arc-based IMRT and adaptive radiotherapy,
offer exciting potential to optimise current toxicity-sparing
radiotherapy strategies and maximise patient beneﬁts.
Reducing dose to certain organs-at-risk does not always
translate into meaningful preservation of long-term func-
tion, however, as highlighted by the mixed outcomes from
other function-sparing radiotherapy trials in HNC [17,19]
and, therefore, we feel it is essential to explore the clinical
beneﬁts of Do-IMRT within the context of a randomised
study, before routine implementation. Here, we review the
evidence base for Do-IMRT in pharyngeal tumours, and
consider how the dysphagia/aspiration-related structures
(DARS) study, our currently accruing multi-centre phase III
randomised controlled trial, may facilitate further incre-
mental beneﬁts in swallowing outcomes.Key Swallowing Structures and Dosimetric
Correlation with Post-radiation Dysphagia
The swallowing process is complex, involving the intri-
cate co-ordination of more than 25 pairs of muscles in the
oropharynx and larynx, and cartilages [20]. Pioneering
work by Eisbruch et al. [21] ﬁrmly established the strong
inﬂuence of pharyngeal constrictor muscles (PCM) and
glottis-supraglottic larynx (GSL) irradiation on persistent
functional impairment after CRT in HNC [21]. Their study
additionally showed that 50 Gy was the lowest maximal
dose delivered to a stricture volume e a surrogate for late
dysphagia, implying that it may be clinically advantageous
to minimise the volumes receiving of 50 Gy (V50) in such
critical DARS. Compared with three-dimensional conformal
radiotherapy, IMRT reduced DARS V50 by 7e10% on average,
consequently motivating a number of centres to analyse thePlease cite this article in press as: Petkar I, et al., Dysphagia-optimised Int
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sures of late dysphagia. In recent years, additional struc-
tures such as the oral cavity and the mylo/geniohyoid
complex have also been implicated with persistent
dysfunction [22,23].
Several statistically signiﬁcant doseeresponse con-
straints for key swallowing structures have been proposed
as a result (Table 1). Strong correlations exist between both
partial volume doses and mean doses with persistent
dysphagia outcomes, implying that the mean dose as a
solitary dosimetric variable should sufﬁce for planning
optimisation [33].
Despite an abundance of published literature, it is chal-
lenging to make unequivocal conclusions regarding the
optimal swallow-sparing parameters. The systematic review
by Duprez et al. [34], which concurred that themean dose to
the PCM was a strong predictor of subsequent functional
impairment, highlighted a number of crucial methodolog-
ical and statistical variations among the analysed studies
that hindered the validity of the review’s outcomes. Signif-
icant heterogeneity in a number of confounding and prog-
nostic variables, such as primary tumour location, tumour
stage, use of concomitant chemotherapy, fractionation
schedule and target volume deﬁnition, limit the conclusions
that can be drawn. The robustness of the reported results is
further dilutedwith the predominantly retrospective nature
of most studies, together with small sample sizes and
inconsistent recording of swallowing outcomes.
Nonetheless, what remains undisputed is that reducing
the radiation dose to DARS, without compromising on sur-
vival outcomes, is an absolute prerequisite for improving
long-term swallowing function [18,35]. Furthermore, the
degree of sparing of individual DARS required to generate
potential increments in function will vary, depending upon
the site of the primary tumour. For instance, in primary NPC
and OPC, the superior pharyngeal constrictors (SPC) will
probably be irradiated to a radical dose compared with GSL
and, consequently, more likely to account for swallowing
difﬁculties after treatment completion. Focussed efforts to
reduce the SPC dose in such scenarios will probably be
advantageous, rather than sparing the GSL. Similarly, in
hypopharyngeal cancers, the inferior constrictors and GSL
radiation doses will probably play a more inﬂuential role on
long-term swallowing function.
Having established a deﬁnitive correlation between
DARS and dysphagia, the next step was to direct efforts
prospectively to evaluate the long-term clinical and func-
tional gains, if any, of reducing dose to DARS.Approaches to Reduce Radiation Dose to
Swallowing Structures
Reducing Mean Dose to the Superior Pharyngeal Constrictors
and Supraglottic Larynx Using a Model-based Validation
Approach
Designed and promoted successfully by a consortium of
leading Dutch radiation oncologists primarily for theensity-modulated Radiotherapy Techniques in Pharyngeal Cancers: Is
10.1016/j.clon.2017.02.002
Table 1
Intensity-modulated radiotherapy (IMRT) studies investigating the correlation between radiation dose to swallowing structures and late dysphagia
Reference Patient
no.
Tumour site Treatment
modality
Dysphagia outcome
measure
Dysphagia end point Timing DARS Dosimetric parameters
correlating with late
dysphagia
[24] 36 OPC, NPC CRT VF
UW-QOL
HN-QOL
RTOG/EORTC LRMS
Aspiration
Stricture
Grade 2 ORD
PRD liquids
PRD solids
3 months PCM
GSL
e
PCM
Oesophagus,
PCM
PCM
Mean 60 Gy, V65>50%
V50>50%
Limited cases;
statistical analysis not
possible
Mean dose e TNS
Mean dose e TNS
Mean dose e TNS
[22] 31 OPC CRT MBS
MDADI
OPSE
Composite MDADI
score
Aspiration
6e24 months Anterior OC
SPC
e
e
V30>65%
V55>80%
None predictive
Limited cases,
statistical analysis
not possible
[25] 96 OC, OPC, NPC, HPC,
larynx, unknown
primary, maxillary
sinus
ICþCRT
CRT
RT
PORT
SPS
Video swallow study
Aspiration
Stricture
1e2 months Larynx
IC
IC
Larynx
Mean 48 Gy; V50>21%
Mean 54 Gy; V50 >51%
Mean 54 Gy; V50>51%
V50 >21%
[26] 37 OPC, NPC, HPC,
larynx
ICþCRT MDADI
RTOG/EORTC-scored
dysphagia
MDADI score
ORD
12 months PCM
Suprahyoid
muscles
Nil signiﬁcant
[27] 83 OC, OPC, NPC, HPC,
larynx,
unknown primary
CRT
RT
CetuximabþRT
MBS FT dependence
Aspiration
Stricture requiring
dilatation
12 months Larynx
IPC
Larynx
IPC
SPC
MPC
Mean 51 Gy
V60>12%
Mean 41 Gy, V60>24%
V60>12%
V65>33%
V65 > 75%
[28] 27 OC, OPC, HPC,
larynx, unknown/other
CRT
RT
HNCI QoL score
Weight loss
FT rates
Dietary modiﬁcations
12 months e
AEF
False VC
False VC
Upper OS
Lateral PW
Nil signiﬁcant
Mean 50 Gy, at the
level of false VC
[29] 39 OC, OPC, HPC, larynx,
unknown primary
CRT CTCAE v2.0
UW-QOL
FT dependence >192 days IPC
CPI
Mean 60 Gy; V65>30%;
V60>60%
Dmax 62 Gy
[23] 34 OPC CRT VF Aspiration
Stricture
FT dependence
Aspiration pneumonia
>12 months SPC
MHM
MHM V69 and SPC V70
associated
with late dysphagia
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Table 1 (continued )
Reference Patient
no.
Tumour site Treatment
modality
Dysphagia outcome
measure
Dysphagia end point Timing DARS Dosimetric parameters
correlating with late
dysphagia
[30] 354* OC, OPC, NPC, HPC,
larynx, unknown
primary, other
RT
CRT
RTOG/EORTC LRMS
EORTC QLQ-H&N 35
>grade 2 dysphagia
(primary end point)
Patient-reported
symptoms (secondary
end point)
6 months SPC
SL
Mean dose to both
most predictive of late
toxicity
Different predictive
models were found for
solid food, liquids, soft
food and choking
[31] 259 OC, OPC, NPC, HPC,
larynx
RT
CRT
Other
EORTC QLQ-H&N 35
MBSy
DAHANCA dysphagia
scale
PRD
SPSS, aspiration
>grade 2 dysphagia
3 years GSL
SPC, MPC
Mean dose 55 Gy
Mean dose 60 Gy
[32] 56 OC, OPC, NPC,
larynx,
salivary glands
CRT
ICþCRT
RT, PORT
RTOG/EORTC LRMC >grade 2 dysphagia 6 months SPC V60>70%
AEF, aryepiglottic fold; CPI, cricoid pharyngeal inlet; CRT, chemoradiation; DARS, dysphagia/aspiration-related structures; FT, feeding tube; GSL, glottis-supraglottic larynx; HNCI,
Head and Neck Cancer Inventory; HN-QOL, head and neck quality of life; HPC, hypopharyngeal cancer; IC, induction chemotherapy; IPC, inferior pharyngeal constrictors; MBS,
modiﬁed barium swallow; MHM, myelo-geniohyoid complex; MDADI, MD Anderson Dysphagia Inventory; MPC, middle pharyngeal constrictors; NPC, nasopharyngeal cancer; OC,
oral cavity; OPC, oropharyngeal cancer; OPSE, oropharyngeal swallowing efﬁciency; ORD, observer-rated dysphagia; OS, oesophageal sphincter; PCM, pharyngeal constrictor
muscles; PORT, postoperative radiotherapy; PRD, patient-reported dysphagia; PW, pharyngeal wall; RT, radiotherapy; RTOG/EORTC LRMS, Radiation Therapy Oncology Group/
European Organization for Research and Treatment of Cancer Late Radiation Morbidity Scale; SL, supraglottic larynx; SPC, superior pharyngeal constrictors; SPS, Swallowing Per-
formance Scale; SPSS, Swallowing Performance Status Scale; TNS, threshold not speciﬁed; UW-QOL, University of Washington head and neck-related quality of life; VC, vocal cords;
VF, videoﬂuoroscopy.
* 38% of patients treated with intensity-modulated radiotherapy.
y 65 patients only.
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try, the normal tissue complication probability (NTCP)
model-based concept is described as a practical alternative
to randomised controlled trials, particularly where the
principal aim of a novel radiation technique is toxicity
reduction rather than survival gains. In this multi-step
methodology, any potential beneﬁt predicted during the
early phases is subsequently conﬁrmed by validating its
model-based estimates in a cohort of patients who are
prospectively followed-up [36,37].
Christianen et al. [30] initially determined that mean
doses to the SPC and supraglottic larynx were most pre-
dictive of Radiation Therapy Oncology Group (RTOG) grade
 2 dysphagia at 6 months after treatment completion in a
heterogeneous group of HNC patients. Their subsequent in
silico comparative planning study, in predominantly
pharyngeal cancers, suggested a 8.9% reduction in mean
NTCP (42% versus 33%) for the physician-rated toxicity
scores with swallow-sparing IMRT (SW-IMRT) that was
additionally optimised to reduce doses to SPC, supraglottic
larynx, middle constrictors and oesophageal inlet, in that
order of priority, compared with standard IMRT [38]. DARS-
sparing was achieved by reducing planning target volume
coverage in its vicinity until exactly 98% of the planning
target volume received 95% of the prescribed dose, together
with accepting a moderate shift of dose to non-speciﬁed
tissues, such as the neck muscles and the oral cavity [39].
Absolute gains in NTCP values varied considerably,
depending on the primary tumour site, nodal involvement
and tumour stage. Finally, their model was clinically vali-
dated in a prospective cohort of 186 patients treated with
SW-IMRT, where the mean predicted NTCPSW-IMRT for the
entire group corresponded perfectly with the observed
grade  2 dysphagia prevalence of 22.6%, and was signiﬁ-
cantly lower than the predicted NTCPstandard of 27.5% [40].
The predicted differences were signiﬁcantly larger (24.1%
versus 32.2%) and, importantly, clinically relevant in about
50% of patients with a DNTCP (NTCPstandard e NTCPSW-
IMRT) > 5%, with observed toxicity prevalence of 25.3%. Pa-
tients in this subset typically had higher T stages, primary
OPC or NPC and were treated more oftenwith conventional
radiotherapy or CRT.
The group’s novel SW-IMRT technique did not compro-
mise target volume coverage, a detrimental limitation of
some of the previous planning studies. Likewise, doses to
the major salivary glands did not differ compared with
standard IMRT, crucial as patients’ perceptions of swal-
lowing difﬁculties can often be inﬂuenced to varying de-
grees by co-existing xerostomia [41]. By excluding patients
with grade > 1 dysphagia at baseline, the investigators
ensured that any subsequently reported dysphagia was
purely treatment-related.
Implementing such a model-based approach in routine
clinical practice, however, will be resource- and time-
intensive, with its success reliant on experienced physi-
cists having iteratively to adjust the planning objectives for
DARS until a suitable plan is achieved. Equally, treatment
planning systems with a fully automated or class solution,
where comparatively less effort is required to achieve aPlease cite this article in press as: Petkar I, et al., Dysphagia-optimised Int
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observe a clinical beneﬁt. Crucially, as with any planning
modelling exercise, the predictability of the reported ben-
eﬁts ultimately depends on the robustness of the primary
end point selected to develop the particular model. In that
context, the use of physician-scored, RTOG-graded
dysphagia at 6 months to deﬁne post-radiotherapy long-
term dysphagia is arguably the weakest link of the above
model. The Dutch group justiﬁed the 6 month post-
treatment timeline, as they felt it to be a reliable predictor
of swallowing deterioration at subsequent timeframes. That
is questionable, with numerous HNC studies showing sub-
stantial variation in swallowing outcomes beyond 6months
[5,42]. Furthermore, data recently published by the same
group analysing patterns of RTOG-scored swallowing
dysfunction after HNC treatment established that 23% of
patients could have a clinically relevant change in the
physician-reported dysphagia scores beyond 6 months,
indicating that the 6 month timeline is inconsistent at
predicting future toxicity [43]. The same study additionally
showed the decreasing inﬂuence of radiation dose to
supraglottic larynx over time, leaving the SPC as the sole
signiﬁcant variable.
It must also be emphasised that physician-reported
swallowing scores often do not correlate well with
patient-reported outcomes and, as a primary end point,
may not necessarily provide the best measure of toxicity
outcomes. For instance, in the Dutch group’s model, NTCP-
based reductions in patient-reported swallowing dysfunc-
tion with SW-IMRT were variable and lower than observer-
rated NTCP reductions. Similar inconsistencies between
observer- and subjective-reported dysphagia have also
been reported in other studies, strengthening the argument
for incorporating multidimensional complementary
physician-scored, patient-reported and instrumental swal-
lowing assessments [33,44,45].
Reduce the Radiation Dose to Parts of Dysphagia/Aspiration-
related Structures Outside the Target Volume
Situated in close proximity to the PCM, both medial and
lateral groups of retropharyngeal lymph nodes (RPN) have
been historically included in radiation target volumes for
pharyngeal cancer. As a result, the constrictors usually
receive a substantial radiation dose, making it challenging
to preserve long-term function. Feng et al. [24] observed
that the practice of irradiating the entire uninvolved RPN
compartment was inconsistent with the available evidence
on patterns of nodal spread, as indicated by the paucity of
metastasis to medial RPN in several surgical and radiolog-
ical series. The group postulated that the medial group of
RPN could be safely excluded from OPC target volumes in
their novel Do-IMRT approach, thereby potentially
improving function without affecting survival outcomes.
They prospectively evaluated their hypothesis in a se-
lective group of stage III/IV OPC patients treated with pri-
mary CRT [42]. Parts of PCM, GSL and oesophagus in the
region of the uninvolvedmedial RPNwere spared by setting
an optimal dose constraint <50 Gy in the IMRT planningensity-modulated Radiotherapy Techniques in Pharyngeal Cancers: Is
10.1016/j.clon.2017.02.002
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42 and 32 Gy, respectively, to the spared regions. Corre-
sponding mean doses to the entire structures were 58, 48
and 34 Gy, respectively. With a median follow-up period of
3 years, the clinical outcomes of such dosimetric modula-
tion in this single-arm study were no worse than standard
approaches, with locoregional recurrence-free and disease-
free survival rates of 96% and 88%, respectively. Crucially,
there were no failures observed within or near the spared
region, thereby establishing the safety of this swallow-
sparing technique.
Patient-reported swallowing outcomes from two estab-
lished questionnaires showed worsening soon after the
completion of treatment, with gradual improvement
through 12 months and subsequent stabilisation, whereas
CTCAE v2.0-based observer-reported dysphagia scores at 12
months almost matched baseline levels. Unlike these two
measures of swallowing toxicity, videoﬂuoroscopy-related
scores did not show longitudinal improvements, with no
signiﬁcant reductions observed beyond 3 months after
treatment. The lack of late CTCAE-graded toxicities pre-
cluded any dosimetric analysis of observer-reported toxic-
ities. Mean doses to PCM, GSL and oesophagus correlated
signiﬁcantly with worsening subjective and instrumental
swallowing assessments, and different NTCPs with no
particular threshold were observed with differing end
points. The tolerance doses that estimated a 50% (TD50) and
25% (TD25) probability for videoﬂuoroscopy-assessed
dysphagia were 63 and 56 Gy, respectively, for PCM, and
56 Gy and 39 Gy, respectively, for supraglottic larynx [33].
The corresponding tolerance doses for patient-reported
worsened outcomes were substantially higher, reﬂecting
to some extent the increased sensitivity of videoﬂuoroscopy
to detect patients who aspirated silently.
The above study presents an innovative, practical and
adaptable solution to generate a potentially beneﬁcial
toxicity-mitigating strategy in OPC; integrating existing
knowledge of patterns of nodal disease spread into the
IMRT planning objectives to further reﬁne radiation de-
livery. Although the study only included patients with OPC,
its methodology can be easily extended to other pharyngeal
tumours too. A novel hypothesis at the time of study design,
the concept of sparing the medial RPN from target volumes
has been endorsed in the recently updated HNC nodal
outlining consensus guidelines [46]. A relatively favourable
patient-reported toxicity outcome, together with minimal
physician-graded toxicity scores, supports the application
of similar dysphagia-optimising strategies in randomised
studies to better deﬁne its true beneﬁts. Notably, the group
has also reported that HR-QoL seems to remain stable with
longer follow-up, with new late toxicity uncommon beyond
2 years [47].
It is clear that the above strategy cannot be extrapolated
to all OPC; the study was selective by excluding any tumour
with posterior pharyngeal wall or RPN involvement,
explaining to a certain extent the excellent survival rates
reported. The absence of a steep doseeresponse curve
makes it difﬁcult to establish deﬁnitive IMRT dose con-
straints for PCM and GSL, although the study authors havePlease cite this article in press as: Petkar I, et al., Dysphagia-optimised Int
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guide their planning objectives at their centre. Sharp dose
fall-offs would be expected in the regions of the spared
structures, and currently available routine imaging tech-
niques do not yet possess the required sensitivity to accu-
rately deﬁne the mucosal extent of tumours; target
contouring, therefore, would need to be more generous in
such scenarios to reduce the risk of marginal recurrence,
which eventually would prove to be counter-productive to
the primary goal of toxicity reduction. Finally, attempting to
spare the medial RPN with IMRTmay result in a dose splash
to adjacent structures linked to swallowing dysfunction,
such as the salivary glands and oral cavity, which could
potentially worsen long-term functional outcomes.The Dysphagia/Aspiration-related
Structures (DARS) Study
The above review elucidates key unambiguous points
that should drive future Do-IMRT research strategies. First, a
strong relationship exists between pharyngeal constrictor
irradiation and long-term swallowing dysfunction in
pharyngeal cancer, implying the need to spare this group of
muscles as much as possible to preserve meaningful long-
term function. Second, signiﬁcant disparity exists between
physician-reported outcomes and patients’ perceptions of
swallowing difﬁculties, making it imperative to include
both subjective and objective measures of swallowing as-
sessments to guide future toxicity-sparing strategies,
particularly in the absence of a universally acceptable
benchmark to measure swallowing function. Finally, in an
era of evidence-based medicine, the lack of a gold-standard
randomised study conﬁrming the superiority of dysphagia-
optimising radiation strategies affects the robustness of any
perceived beneﬁts reported so far and limits its incorpora-
tion into routine clinical practice.
The Cancer Research UK-funded DARS trial is currently
open to recruitment and integrates the above core themes
into its study design. Its results should provide a sound
evidence base regarding the clinical and functional beneﬁts
of Do-IMRT in the future. The study is a UK multi-centre
phase III randomised clinical trial with blinded assess-
ments of key outcome measures, in patients undergoing
radical primary CRT or radiation alone, for T1-4, N0-3, M0
primary pharyngeal cancer not involving the RPN or pos-
terior pharyngeal wall and requiring bilateral neck irradia-
tion [48]. Eligible patients will be randomised to either
standard IMRTor Do-IMRT, where the mean dose to parts of
pharyngeal constrictors lying outside the radical treatment
volumes will be limited to<50 Gy. The primary objective of
the study is to determine whether Do-IMRT improves
swallowing outcomes, which will be evaluated as a patient-
reported outcome using the MD Anderson Dysphagia In-
ventory (MDADI) composite score. The difference in the
mean MDADI composite scores at 12 months after treat-
ment completion between the two arms forms the primary
end point of the trial. The MDADI composite score is a
feasible, sensitive and validated patient-reported, swallow-ensity-modulated Radiotherapy Techniques in Pharyngeal Cancers: Is
10.1016/j.clon.2017.02.002
Fig 1. (A) Axial computed tomography scan showing gross tumour volume (red), clinical target volume (CTV1) for radical dose radiotherapy (red
with arrow), CTV2 for prophylactic dose radiotherapy (cyan), superior/middle pharyngeal constrictor (SMPCM; yellow). (B) SMPCM lying outside
CTV1 edited to create PlanSMPCM (pink). (C) PlanSMPCM is set a mean dose constraint of <50 Gy in the planning objectives.
I. Petkar et al. / Clinical Oncology xxx (2017) 1e9 7speciﬁc questionnaire, designed for use speciﬁcally in the
HNC population [49,50]. This 19-item quick to complete,
written questionnaire integrates information from a pa-
tient’s physical, emotional and functional level at various
recovery points after treatment completion to generate an
overall impairment score [5]. The MDADI is increasingly
adopted in a number of head and neck studies as a func-
tional outcome tool [51,52]. In addition to MDADI, swal-
lowing outcomes will be comprehensively assessed using a
multidimensional, longitudinal panel of objective and sub-
jective functional outcome measures.
The planning technique is an adaptation of the meth-
odology introduced by Feng et al. [42] and uses varying dose
constraints for constrictor muscles depending upon the
primary tumour site (Figure 1).Conclusion
Evidence from the published literature on swallow-
sparing radiotherapy strategies suggests that this
approach is promising and requires further validation to
conﬁrm its clinical impact. As our quest for the optimal
dysphagia-sparing radiotherapy strategy continues,
encouraging dosimetric data are beginning to emerge for
rotational IMRT [53] and, together with adaptive radio-
therapy, this represents the next phase of investigative ef-
forts to improve swallowing function. It is important to
appreciate, however, that improvements in long-term
swallow achievable through technological innovations in
IMRT are ﬁnite, and by itself unlikely to eradicate delete-
rious post-radiation effects. Rather, it will serve as a useful
adjunct to other modalities exploring similar end points.
The role of protons is generating increasing interest, with
retrospective toxicity-sparing outcomes emerging from
single-centre institutions [54,55]. In the absence of rando-
mised data though, it remains contentious whether any
perceived beneﬁts justify the high capital investment pro-
tons require, particularly in the current environment of
stringent healthcare budgets. Strategies involving de-
escalation of chemotherapy and radiotherapy [56],Please cite this article in press as: Petkar I, et al., Dysphagia-optimised Int
Anyone Going to Swallow it? Clinical Oncology (2017), http://dx.doi.org/improving management of acute toxicities [57,58], using
functional imaging to adapt radiotherapy [59], strength-
ening collaboration with speech and language therapists
and dietetics to facilitate timely swallowing interventions
and evaluating novel drugeradiotherapy combinations are
some of the key measures that need to be incorporated to
ultimately devise a successful personalised toxicity-
mitigating approach in pharyngeal cancer.
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